# Edesa Biotech Inc. (EDSA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $69M  
**Price:** $5.21 (+5.47%)

> Edesa Biotech Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and gastrointestinal indications. The company's primary purpose is to address unmet medical needs by leveraging its proprietary research and extensive clinical expertise to create novel treatment options. Edesa Biotech Inc. specializes in small molecule drugs and biologics, targeting conditions where existing therapies are inadequate or non-existent. Notably, the company's pipeline includes potential treatments for atopic dermatitis and allergic contact dermatitis, aiming to improve patient outcomes in skin health. Situated in a competitive biotech industry, Edesa Biotech plays a significant role by contributing to medical advancement and potential breakthrough treatments in dermatology. Through its dedication to clinical trials and regulatory approvals, Edesa Biotech strives to enhance its market position and impact healthcare practices worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2021 | — | — | -$24M | -$13M | — |
| 2020 | $328,801 | $311,200 | -$6M | -$6M | — |
| 2018 | — | — | -$2M | -$2M | — |
| 2018 | $211,849 | $78,533 | -$5M | -$5M | — |
| 2017 | $228,287 | -$21,755 | -$5M | -$5M | — |
| 2016 | $1M | $453,123 | -$5M | -$5M | $-0.57 |
| 2015 | $758,689 | $177,865 | -$4M | -$3M | $-0.36 |
| 2014 | $372,132 | -$97,017 | -$6M | -$8M | $-1.11 |
| 2013 | $545,469 | $488,118 | — | -$14M | $-2.81 |
| 2012 | $286,054 | -$140,256 | — | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2021 | $15M | $2M | $13M | $8M | — |
| 2020 | $11M | $2M | $7M | $7M | — |
| 2018 | $3M | $183,820 | $3M | $3M | — |
| 2018 | $12M | $8M | $4M | $4M | — |
| 2017 | $8M | $320,947 | $7M | $5M | — |
| 2016 | $13M | $623,644 | $12M | $7M | — |
| 2015 | $10M | $2M | $8M | $4M | — |
| 2014 | $14M | $7M | $8M | $8M | — |
| 2013 | $9M | $11M | -$2M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$7M | — | — |
| 2024 | -$5M | — | — |
| 2023 | -$7M | — | -$7M |
| 2022 | -$12M | $5,656 | -$12M |
| 2021 | -$14M | $6,146 | -$14M |
| 2020 | -$5M | $4,856 | -$5M |
| 2018 | -$1M | $6,869 | -$1M |
| 2018 | -$5M | $382,810 | -$5M |
| 2017 | -$5M | $302,733 | -$5M |
| 2016 | -$5M | $402,271 | -$5M |
| 2015 | -$4M | $274,589 | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/EDSA)